Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines for Pharmacy. Please see the bottom of the page for full disclaimer.
View Xarelto (rivaroxaban) prescribing information and adverse event reporting information
If the PDF does not load within 5 seconds, please refresh the page.
For additional information consult:
- SmPC for Xarelto (rivaroxaban): www.medicines.org.uk/emc/product/2793
- For further resources relating to rivaroxaban and NVAF: www.xarelto.co.uk
- For patient information leaflets: www.xarelto.co.uk/patients-atrial-fibrillation
NVAF=non-valvular atrial fibrillation; SmPC=summary of product characteristics
This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines for Pharmacy. Bayer plc carried out approval to ensure compliance with regulations. No part of this publication may be reproduced in any form without the permission of the publisher.
PP-XAR-GB-2054
Date of preparation: April 2021